Stress Clinical Trial
Official title:
Proof of Effectiveness of Pascoflair Using Qantitative Measurement of Electric Brain Activity During Examination Stress in 40 Subjects Suffering From Test Anxiety. A Double-blind, Randomized, Placebo-controlled, 2-armed, Phase IV Study in Parallel Design.
NCT number | NCT05049447 |
Other study ID # | 200S14PF |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | May 2015 |
Est. completion date | August 2015 |
Verified date | September 2021 |
Source | Pascoe Pharmazeutische Praeparate GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Proof of effectiveness of Pascoflair using qantitative measurement of electric brain activity during examination stress in 40 subjects suffering from test anxiety. A double-blind, randomized, placebo-controlled, 2-armed, Phase IV study in parallel design.
Status | Completed |
Enrollment | 40 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Healthy male and female subjects. - Age between 18 and 40 years (both included). - Anxiety questionnaire PAF (pre-selection of subjects) - values above T> 60 are regarded as conclusive. - Inconclusive case history and diagnosis. - Subject must be capable of giving informed consent. - Acceptance of written consent to participate in the study after education in written and oral form (informed consent). Exclusion Criteria: - Acute or chronic disease with an impact on the study, which becomes obvious by case history or clinical examination. - Clinically relevant pathological findings from clinical and laboratory findings. - Presence of clinically relevant pathological EEG features or artifact-free portion of the screening EEG <30%. - Clinically relevant allergic symptoms. - Detection of alcohol at the time of initial examination (day SC) or on study day A (positive alcohol test) or by case history. - Detection of drugs (positive drug test) at the time of initial examination (day SC). - Consumption of clinically relevant medication during last fourteen days before and during the active study period based on the notification of the subject or his case history. - Consumption of medication with primarily central action (i.e. psychotropic drugs or centrally acting antihypertensives). - Known intolerance / hypersensitivity (allergy) to plant derived extracts (Passion flower dry extract) or any of the ingredients of the investigational product (anamnestic). - Presence of a rare, genetic disease such as fructose intolerance, glucosegalactose malabsorption or sucrase-isomaltase deficiency (anamnestic). - BMI (Body Mass Index) <18 or> 32. - Consumption of unusual quantities or misuse of coffee (more than 4 cups a day), tea (more than 4 cups a day) or tobacco (more than 20 cigarettes per day). - Smoking on day of A. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Pascoe Pharmazeutische Praeparate GmbH | NeuroCode AG |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of verum and placebo Beta 1 power | Comparison of verum and placebo efficacy is performed on electric power in 17 different brain regions within six frequency ranges defined as target parameters in the presence of different stress inducing cognitive tests or exciting video scenes | day A (treatment day) - 1 day | |
Secondary | Tolerability in a 4- Point scale | Tolerability in a 4- Point scale (very good, good, moderately, poor) | Final examination (day AB) -1 day | |
Secondary | Correlation between questionnaire items and spectral EEG power with regard to different frequency ranges. | Correlation between questionnaire items and spectral EEG power with regard to different frequency ranges. | Final examination - 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05130944 -
Feasibility of Community Psychosocial Intervention for Women
|
N/A | |
Recruiting |
NCT06079853 -
Nurse Suicide: Physiologic Sleep Health Promotion Trial
|
N/A | |
Completed |
NCT05881681 -
A Mindfulness Approach to UA for Afro-descendants
|
N/A | |
Recruiting |
NCT05449002 -
Digital Single Session Intervention for Youth Mental Health
|
N/A | |
Recruiting |
NCT04038190 -
A Behavioral Activation Intervention Administered in a College Freshman Orientation Course
|
Phase 2 | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Active, not recruiting |
NCT05998161 -
Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout
|
N/A | |
Completed |
NCT03728062 -
Mindfulness Meditation Versus Physical Exercise: Comparing Effects on Stress and Immunocompetence
|
N/A | |
Terminated |
NCT04367636 -
The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19
|
N/A | |
Completed |
NCT06405789 -
The Effect of Yoga on Mindfulness and Perceived Stress
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Completed |
NCT05245409 -
Stress, EEG, ECG, and Chiropractic
|
N/A | |
Completed |
NCT04722367 -
Being Present With Art: The Impact of Mindful Engagement With Art on Awareness and Connection
|
N/A | |
Recruiting |
NCT06273228 -
Parenting Young Children in Pediatrics
|
N/A | |
Completed |
NCT06057883 -
Effects Of A Probiotic Formulation On Stress and Skin Health in Younger Adult Females
|
Phase 2 | |
Completed |
NCT05063305 -
Probiotics, Immunity, Stress, and QofL
|
N/A | |
Completed |
NCT05312749 -
The Effect of Web Based Progressive Muscle Relaxation Exercise on Clinical Stress and Anxiety of Nursing Students
|
N/A | |
Completed |
NCT05623826 -
Feasibility and Efficacy of a Digital Training Intervention to Increase Reward Sensitivity- Imager
|
N/A | |
Completed |
NCT04013451 -
The Kiss of Kindness Study II
|
N/A |